Martine Keenan

Title: Martine Keenan: Innovator in Neurotransmission Modulation

Introduction

Martine Keenan is a prominent inventor based in Basingstoke, GB. She has made significant contributions to the field of neurotransmission modulation, holding two patents that focus on the modulation of acetylcholine receptors. Her work is particularly relevant for the treatment of dysfunctions in the central and autonomic nervous systems.

Latest Patents

Keenan's latest patents include "Aza-cyclic compounds as modulators of acetylcholine receptors" and "Modulators of acetylcholine receptors." The first patent discloses compounds that comprise an aza-cyclic portion and an aromatic portion linked via a sulphur atom. These compounds are selective modulators of the beta 4 subtype nicotinic acetylcholine receptors, which are useful for treating various dysfunctions of the nervous system. The second patent relates to thio-bridged aryl compounds that promote the release of neurotransmitters such as acetylcholine, dopamine, and norepinephrine. These compounds also aim to modulate acetylcholine receptors and are beneficial for addressing dysfunctions in the nervous systems.

Career Highlights

Throughout her career, Martine Keenan has worked with notable companies, including Merck & Company, Inc. and Merck + Co., Inc. Her experience in these organizations has contributed to her expertise in the field of pharmaceutical innovations.

Collaborations

Keenan has collaborated with esteemed colleagues such as Peter Charles Astles and Stephen Richard Baker. These partnerships have likely enhanced her research and development efforts in neurotransmission modulation.

Conclusion

Martine Keenan's innovative work in the field of neurotransmission modulation has the potential to significantly impact the treatment of nervous system dysfunctions. Her patents reflect her dedication to advancing medical science and improving patient outcomes.